WuXi Biologics 2021 at a Glance
Global Regulatory Inspection Record
In 2021, we passed 15 regulatory inspections of our GMP manufacturing and testing facilities in China and Germany, and so far we have completed 21 inspections from the U.S. FDA, EMA, PMDA, NMPA, HSA, Health Canada, ANVISA and the WHO.
WuXi Biologics' Efforts in the Fight against COVID-19

As a global corporate citizen, WuXi Biologics is enabling and working with global partners in the fight against the pandemic.

20+ COVID-19 programs for 29+ INDs approved globally
WuXi Biologics' 10th Anniversary

In 2021, we celebrated the 10th Anniversary of WuXi Biologics in our China, U.S., Ireland and Germany sites. Over the past ten years, we've built a highly-experienced and industry-leading organization with over 9,500 employee globally.
First GMP Production at 24,000L Line of MFG5 Facility Successfully Completed at WuXi Biologics Read More

WuXi Biologics Launches a New GMP Commercial Drug Product Facility
WuXi Biologics Congratulates Amicus on U.S. FDA’s Acceptance of its Filing for AT-GAA for the Treatment of Pompe Disease

WuXi Biologics Congratulates Emergency Use Authorization of Sotrovimab for the treatment of COVID-19 Read More
JPM Health Care Conference
Peptalk 2022
Follow Us!